Staphylococcus aureus Hemolysin A Specific Neutra™ Antibody Products
Product listAccelerate Your Research and Development!
Are you currently facing challenges in studying Staphylococcus aureus pathogenesis, developing effective anti-virulence therapies, or creating highly specific diagnostic tools? At Creative Biolabs, our S. aureus Hemolysin A Specific Antibody Products are designed to help you overcome these hurdles. We provide highly characterized antibodies that enable precise detection and neutralization of a key bacterial virulence factor, supporting robust research and the development of novel anti-infective strategies through our advanced antibody discovery platform.
Contact our team to get an inquiry now!
Introduction of S. aureus Hemolysin A
Staphylococcus aureus Hemolysin A (Hla) is the prototypic member of the beta-barrel pore-forming toxin family. It is secreted as a water-soluble monomer that, upon binding to its receptor on the surface of target cells, undergoes oligomerization to form a heptameric pre-pore structure. This complex then inserts into the host cell membrane, creating a stable, transmembrane pore with a diameter of approximately 14 Å. This pore allows the uncontrolled efflux of essential ions, such as K+, and influx of Ca2+, leading to rapid disruption of the cell's osmotic balance and subsequent necrotic cell death. The cytotoxic effects of Hla contribute to severe infections, including necrotizing pneumonia, skin abscesses, and sepsis. The toxin's ability to compromise epithelial and endothelial barriers also facilitates bacterial dissemination into deeper tissues and the bloodstream.
Fig.1 Hemolytic phenotype comparative analyses of S. aureus in blood agar plates.1
Our Anti-S. aureus Hemolysin A Antibody Products
Antibodies targeting S. aureus Hemolysin A are essential for both research and potential therapeutic applications. By binding to the Hla protein, these antibodies can prevent its crucial oligomerization step on the host cell membrane, thereby neutralizing its pore-forming activity. In research, anti-Hla antibodies are used to detect and quantify the toxin in bacterial cultures, patient samples, or experimental models. They are invaluable for Western Blotting to confirm Hla expression, for ELISA to measure toxin concentration, and for IHC to localize the toxin in infected tissues. Therapeutically, the neutralization of Hla by specific antibodies represents a promising strategy for passive immunization. Published data from preclinical studies have shown that administering Hla-neutralizing antibodies can significantly reduce the severity of S. aureus infections in animal models, offering a new approach to combat antibiotic-resistant strains by targeting virulence rather than bacterial growth.
Why Choose Us?
Creative Biolabs is a trusted partner in the biopharmaceutical industry, with a proven track record of delivering high-quality, reliable antibody products. Our S. aureus Hemolysin A specific antibodies are developed through a rigorous process to ensure exceptional performance.
- Exceptional Specificity: Our antibodies are meticulously screened and validated to ensure high specificity for Hemolysin A, minimizing cross-reactivity with other S. aureus toxins and host proteins.
- High Neutralizing Potency: We focus on developing antibodies that potently neutralize the hemolytic activity of Hla, providing a robust tool for functional assays and therapeutic research.
- Diverse Applications: Whether your project requires antibodies for basic research or for the development of diagnostic assays, our products are suitable for a wide range of applications, saving you time and resources.
- Proven Efficacy: Supported by Published Data, our antibodies have demonstrated their effectiveness in various research settings, providing you with a reliable and well-documented solution.
Creative Biolabs provides a comprehensive portfolio of high-performance S. aureus Hemolysin A Specific Antibody Products, meticulously designed to meet the demanding needs of academic and industrial research. By offering precision, specificity, and documented performance, we empower you to accelerate your projects in infectious disease research and anti-virulence drug discovery. Our commitment to quality and scientific excellence ensures you have the reliable tools you need to succeed.
Access the Creative Biolabs Edge – Request Your Quote Now
FAQs
Q: How can these antibodies be used to study S. aureus infections?
A: Our antibodies are versatile tools for investigating the role of Hla in pathogenesis. They can be used to neutralize the toxin's effects in cell culture or animal models, allowing you to study how blocking Hla impacts disease progression. You can also use them to detect the presence and quantity of Hla in various samples, providing insights into toxin production during infection.
Q: Are these antibodies suitable for neutralizing the pore-forming activity of the toxin?
A: Yes, our antibodies are specifically designed to inhibit the key steps in the toxin's mechanism of action. By binding to Hla, they prevent the protein from assembling into its active pore structure, thereby neutralizing its cytotoxic effects on host cells. This makes them highly effective for in vitro and in vivo neutralization studies.
Q: What types of samples are compatible with these antibodies?
A: The antibodies are validated for use with a range of sample types, including bacterial culture supernatants, infected tissue sections, and complex biological fluids. Their robust design ensures reliable performance across diverse matrices.
Q: Can these antibodies be used in conjunction with other anti-virulence strategies?
A: Absolutely. Our antibodies can be integrated into multifaceted research approaches. They are ideal for studies combining Hla neutralization with other therapeutic agents, allowing for the investigation of synergistic effects in combating S. aureus virulence and antibiotic resistance.
Q: Is there any risk of cross-reactivity with other related toxins?
A: Our antibodies are highly specific for Hemolysin A. Each product undergoes rigorous validation to ensure minimal cross-reactivity with other staphylococcal toxins, providing you with confidence in the accuracy and reliability of your results.
REFERENCE
- Zhang, Haifang et al. "Identification and Characterization of Staphylococcus aureus Strains with an Incomplete Hemolytic Phenotype." Frontiers in cellular and infection microbiology vol. 6 146. 18 Nov. 2016, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fcimb.2016.00146
